Trulieve Cannabis Corp. TCNNF
We take great care to ensure that the data presented and summarized in this overview for Trulieve Cannabis Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TCNNF
View all-
Albert D Mason Inc43.5KShares$262,3650.41% of portfolio
-
Gofen & Glossberg LLC13.4KShares$80,9040.0% of portfolio
-
Canton Hathaway, LLC4.1KShares$24,7230.01% of portfolio
-
Westside Investment Management, Inc.500Shares$3,0150.0% of portfolio
-
Horrell Capital Management, Inc.80Shares$4820.0% of portfolio
-
Org Partners LLC Roanoke, IN75Shares$4520.0% of portfolio
-
Mfa Wealth Advisors, LLC Pittsburgh, PA33Shares$1980.0% of portfolio
-
Strategic Investment Solutions, Inc. /Il Orland Park, IL25Shares$1500.0% of portfolio
-
Hantz Financial Services, Inc.2Shares$120.0% of portfolio
Latest Institutional Activity in TCNNF
Top Purchases
Top Sells
About TCNNF
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The company produces flower, edible, vaporizer cartridge, concentrate, topical, capsule, tincture, dissolvable powder, and nasal spray products under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands. As of March 16, 2022, it operated 162 dispensaries, which included 113 dispensaries in Florida, 19 affiliated dispensaries in Pennsylvania, 17 dispensaries in Arizona, five dispensaries in California, three dispensaries in Maryland, two dispensaries in Massachusetts, two dispensaries in West Virginia, and one dispensary in Connecticut. Trulieve Cannabis Corp. also operated cultivation and processing facilities in Arizona, Colorado, Florida, Maryland, Massachusetts, Nevada, Pennsylvania, and West Virginia. The company was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Quincy, Florida.
Insider Transactions at TCNNF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
Wes Getman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,500
+16.81%
|
$38,000
$4.91 P/Share
|
|
Dec 01
2024
|
Kim A. Rivers Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
38,475
-1.96%
|
$230,850
$6.03 P/Share
|
|
Dec 01
2024
|
Nilyum Jhala Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,003
-6.1%
|
$42,018
$6.03 P/Share
|
|
Dec 01
2024
|
Joy Malivuk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,941
-7.06%
|
$17,646
$6.03 P/Share
|
|
Dec 01
2024
|
Eric Powers Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,003
-5.79%
|
$42,018
$6.03 P/Share
|
|
Dec 01
2024
|
Timothy Morey Chief Sales Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,536
-5.77%
|
$39,216
$6.03 P/Share
|
|
Dec 01
2024
|
Gina Collins Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,003
-6.74%
|
$42,018
$6.03 P/Share
|
|
Dec 01
2024
|
Kyle Landrum Chief Production Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,003
-5.2%
|
$42,018
$6.03 P/Share
|
|
Nov 21
2024
|
Peter Healy Director |
BUY
Open market or private purchase
|
Direct |
8,130
+20.98%
|
$48,780
$6.05 P/Share
|
|
Nov 21
2024
|
Jane C Morreau Director |
BUY
Open market or private purchase
|
Direct |
1,235
+4.95%
|
$7,410
$6.06 P/Share
|
|
Nov 21
2024
|
Richard S. May Director |
BUY
Open market or private purchase
|
Direct |
1,160
+0.21%
|
$6,960
$6.05 P/Share
|
|
Nov 20
2024
|
Susan Thronson Director |
BUY
Open market or private purchase
|
Direct |
3,968
+13.04%
|
$23,808
$6.3 P/Share
|
|
Nov 19
2024
|
Thomas L Millner Director |
BUY
Open market or private purchase
|
Direct |
8,000
+20.78%
|
$48,000
$6.12 P/Share
|
|
Nov 15
2024
|
Thad Beshears Director |
BUY
Open market or private purchase
|
Direct |
7,500
+0.31%
|
$45,000
$6.65 P/Share
|
|
Nov 15
2024
|
Kim A. Rivers Chairman and CEO |
BUY
Open market or private purchase
|
Direct |
7,400
+0.37%
|
$44,400
$6.65 P/Share
|
|
Nov 13
2024
|
Eric Powers Chief Legal Officer |
BUY
Open market or private purchase
|
Indirect |
1,000
+50.0%
|
$6,000
$6.1 P/Share
|
|
Nov 12
2024
|
Gina Collins Chief Marketing Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+1.19%
|
$7,500
$6.37 P/Share
|
|
Nov 12
2024
|
Nilyum Jhala Chief Technology Officer |
BUY
Open market or private purchase
|
Indirect |
2,500
+29.41%
|
$15,000
$6.32 P/Share
|
|
Nov 11
2024
|
Nilyum Jhala Chief Technology Officer |
BUY
Open market or private purchase
|
Indirect |
2,000
+36.36%
|
$10,000
$5.7 P/Share
|
|
Nov 11
2024
|
Kyle Landrum Chief Production Officer |
BUY
Open market or private purchase
|
Direct |
3,800
+1.39%
|
$22,800
$6.22 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 379K shares |
|---|---|
| Exercise of conversion of derivative security | 39.2K shares |
| Open market or private purchase | 80.2K shares |
| Conversion of derivative security | 3M shares |
| Bona fide gift | 3M shares |
| Sale (or disposition) back to the issuer | 15.9K shares |
|---|---|
| Open market or private sale | 1.07K shares |
| Payment of exercise price or tax liability | 949K shares |
| Bona fide gift | 3M shares |